— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected.
— Revenue grew 65% to $98.3 million vs. $97.76 million expected.
— For FY20, NUPLAZID sales is expected to be between $440 million and $470 million.
— For fiscal 2020, GAAP R&D expense is expected to be between $270 and $285 million and GAAP SG&A expense is expected to be between $440 and $460 million.
— ACAD shares rose about 4% following the earnings announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
MU Earnings: Micron Q2 profit jumps on higher revenues, tops expectations
Semiconductor company Micron Technology Inc. (NASDAQ: MU) Thursday reported a sharp increase in revenues and earnings for the second quarter of 2025. Earnings also surpassed Wall Street's forecasts. The Idaho-headquartered
Darden Restaurants sees growth in FY25 and beyond amid menu, tech Innovations
Darden Restaurants, Inc. (NYSE: DRI) has successfully navigated the challenging market environment by constantly innovating its menu offerings and fostering customer loyalty. In the third quarter, sales and profit margin
What to look for when McCormick & Company (MKC) reports Q1 2025 earnings
Shares of McCormick & Company, Incorporated (NYSE: MKC) were down 1% on Thursday. The stock has gained 5% year-to-date. The spice giant is slated to report its first quarter 2025 earnings results
